Harmony Biosciences (HRMY) Financials

$29.61 +0.18 (+0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$29.62 +0.01 (+0.03%)

As of 04:05 PM Eastern

Annual Income Statements for Harmony Biosciences

This table shows Harmony Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-187	-64	35	181	129	146
Consolidated Net Income / (Loss)	-152	-37	35	181	129	145
Net Income / (Loss) Continuing Operations	-152	-37	35	181	129	145
Total Pre-Tax Income	-152	-37	37	105	173	192
Total Operating Income	-146	17	88	120	192	191
Total Gross Profit	4.42	132	250	354	461	558
Total Revenue	6.00	160	305	438	582	715
Operating Revenue	6.00	160	305	438	582	715
Total Cost of Revenue	1.58	28	56	83	121	157
Operating Cost of Revenue	1.58	28	56	83	121	157
Total Operating Expenses	150	115	162	234	269	367
Selling, General & Admin Expense	36	40	64	84	95	110
Marketing Expense	44	56	68	79	97	111
Research & Development Expense	70	19	30	71	76	146
Total Other Income / (Expense), net	-6.07	-54	-50	-16	-19	0.98
Interest Expense	0.00	23	50	19	34	17
Interest & Investment Income	-6.07	-28	0.22	3.13	15	19
Other Income / (Expense), net	0.00	-3.07	0.02	0.17	-	-0.07
Income Tax Expense	0.00	0.00	2.83	-77	45	46
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	0.00	0.15	-0.15	-0.06
Basic Earnings per Share	($24.07)	($2.48)	$0.60	$3.07	$2.17	$2.56
Weighted Average Basic Shares Outstanding	7.78M	25.77M	57.53M	59.17M	59.47M	56.89M
Diluted Earnings per Share	($24.07)	($2.48)	$0.58	$2.97	$2.13	$2.51
Weighted Average Diluted Shares Outstanding	7.78M	25.77M	59.21M	61.10M	60.37M	57.87M
Weighted Average Basic & Diluted Shares Outstanding	-	56.89M	58.87M	59.62M	56.77M	57.35M

This table shows Harmony Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	88	49	30	34	38	27	38	12	47	49
Consolidated Net Income / (Loss)	88	49	29	34	38	27	38	12	46	49
Net Income / (Loss) Continuing Operations	88	49	29	34	38	27	38	12	46	49
Total Pre-Tax Income	7.97	44	38	44	52	40	52	22	62	56
Total Operating Income	12	48	40	47	65	40	52	21	62	56
Total Gross Profit	94	101	98	109	128	125	127	141	143	147
Total Revenue	117	128	119	134	160	168	155	173	186	201
Operating Revenue	117	128	119	134	160	168	155	173	186	201
Total Cost of Revenue	23	27	21	25	32	43	27	32	43	54
Operating Cost of Revenue	23	27	21	25	32	43	27	32	43	54
Total Operating Expenses	82	54	58	62	63	85	75	119	82	91
Selling, General & Admin Expense	21	23	22	23	23	28	26	27	29	29
Marketing Expense	20	21	23	25	23	27	27	29	28	28
Research & Development Expense	41	10	13	15	17	30	22	64	25	35
Total Other Income / (Expense), net	-3.93	-3.51	-2.64	-2.81	-13	-0.67	-0.25	0.34	0.46	0.43
Interest Expense	0.00	-	5.73	6.22	17	4.80	4.54	4.40	4.35	4.21
Interest & Investment Income	-3.99	15	3.09	3.44	4.11	4.10	4.43	4.71	4.93	4.48
Other Income / (Expense), net	0.06	0.07	0.00	-0.03	-0.01	-	-0.14	0.04	-0.12	0.16
Income Tax Expense	-80	-4.41	8.30	9.80	13	13	13	10	16	6.68
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.15	-0.03	-0.12	0.49	-0.01	-0.52	0.17	0.06	-0.73	0.43
Basic Earnings per Share	$1.48	$0.83	$0.49	$0.57	$0.64	$0.47	$0.68	$0.20	$0.81	$0.87
Weighted Average Basic Shares Outstanding	59.23M	59.17M	59.73M	59.97M	59.86M	59.47M	56.77M	56.80M	56.87M	56.89M
Diluted Earnings per Share	$1.44	$0.79	$0.48	$0.56	$0.63	$0.46	$0.67	$0.20	$0.79	$0.85
Weighted Average Diluted Shares Outstanding	61.21M	61.10M	61.22M	60.74M	60.68M	60.37M	57.60M	57.54M	58.10M	57.87M
Weighted Average Basic & Diluted Shares Outstanding	59.32M	59.62M	59.95M	60.00M	58.57M	56.77M	56.79M	56.83M	57.03M	57.35M

This table details how cash moves in and out of Harmony Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-59	204	5.68	9.48	67	141
Net Cash From Operating Activities	-75	-2.99	99	144	219	220
Net Cash From Continuing Operating Activities	-75	-2.99	99	144	219	220
Net Income / (Loss) Continuing Operations	-152	-37	35	181	129	145
Consolidated Net Income / (Loss)	-152	-37	35	181	129	145
Depreciation Expense	0.40	0.39	0.42	0.42	0.51	0.27
Amortization Expense	3.41	12	21	24	23	22
Non-Cash Adjustments To Reconcile Net Income	64	33	42	28	45	88
Changes in Operating Assets and Liabilities, net	8.29	-12	0.63	-90	22	-37
Net Cash From Investing Activities	-127	-2.00	-100	-142	-46	-67
Net Cash From Continuing Investing Activities	-127	-2.00	-100	-142	-46	-67
Purchase of Property, Plant & Equipment	-0.15	-0.00	-0.30	-0.17	-37	-34
Purchase of Investments	-	0.00	0.00	-111	-127	-105
Sale and/or Maturity of Investments	-	0.00	0.00	9.07	118	99
Other Investing Activities, net	-127	-2.00	-100	-40	-	-27
Net Cash From Financing Activities	144	209	7.42	6.84	-106	-11
Net Cash From Continuing Financing Activities	144	209	7.42	6.84	-106	-11
Repayment of Debt	-5.18	-126	-232	-2.00	-210	-15
Repurchase of Common Equity	0.00	-0.17	-0.30	0.00	-100	0.00
Issuance of Debt	100	200	200	0.00	200	0.00
Other Financing Activities, net	0.09	-12	9.37	8.84	4.54	4.00
Cash Interest Paid	4.23	26	20	16	20	17
Cash Income Taxes Paid	0.00	0.00	2.88	13	48	80

This table details how cash moves in and out of Harmony Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	25	-18	44	29	7.19	-13	21	-16	70	66
Net Cash From Operating Activities	55	27	43	37	63	77	31	43	71	76
Net Cash From Continuing Operating Activities	55	27	43	37	63	77	31	43	71	76
Net Income / (Loss) Continuing Operations	88	49	29	34	38	27	38	12	46	49
Consolidated Net Income / (Loss)	88	49	29	34	38	27	38	12	46	49
Depreciation Expense	0.10	0.11	0.10	0.10	0.14	0.16	0.16	0.09	0.01	0.01
Amortization Expense	6.38	5.95	5.74	5.71	6.49	5.46	5.55	5.51	5.59	5.64
Non-Cash Adjustments To Reconcile Net Income	7.24	8.16	6.93	8.22	18	12	11	54	12	11
Changes in Operating Assets and Liabilities, net	-46	-36	0.30	-11	-0.18	33	-24	-29	6.87	9.10
Net Cash From Investing Activities	-32	-47	-1.79	-7.77	-0.81	-36	-6.19	-55	0.75	-7.19
Net Cash From Continuing Investing Activities	-32	-47	-1.79	-7.77	-0.81	-36	-6.19	-55	0.75	-7.19
Purchase of Property, Plant & Equipment	-0.09	-	0.00	-0.21	-	-37	-0.01	-0.63	-0.00	-34
Purchase of Investments	-33	-55	-48	-25	-33	-22	-25	-21	-23	-36
Sale and/or Maturity of Investments	0.87	8.20	46	18	32	23	19	26	24	30
Other Investing Activities, net	-	-	-	-	-	-	-	-	-	-1.00
Net Cash From Financing Activities	2.05	2.66	3.41	-0.34	-55	-54	-3.63	-3.45	-1.18	-2.74
Net Cash From Continuing Financing Activities	2.05	2.66	3.41	-0.34	-55	-54	-3.63	-3.45	-1.18	-2.74
Repayment of Debt	-0.50	-0.50	-0.50	-0.50	-205	-3.75	-3.75	-3.75	-3.75	-3.75
Other Financing Activities, net	2.14	3.57	3.91	0.16	0.24	0.23	0.12	0.30	2.58	1.01
Cash Interest Paid	3.81	5.03	5.02	5.67	4.96	4.40	4.59	4.36	4.23	4.15
Cash Income Taxes Paid	9.41	2.94	-	-	17	12	-	-	16	21

This table presents Harmony Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Total Assets	107	427	433	674	811	999
Total Current Assets	31	263	284	400	451	579
Cash & Equivalents	24	229	234	244	312	453
Short-Term Investments	-	-	0.00	79	42	14
Accounts Receivable	4.26	22	35	55	74	83
Inventories, net	1.09	3.82	4.43	4.30	5.36	7.20
Prepaid Expenses	1.44	6.96	7.64	9.35	13	14
Other Current Assets	0.26	1.30	3.22	8.79	5.54	8.12
Plant, Property, & Equipment, net	1.33	0.94	0.82	0.57	0.37	1.26
Total Noncurrent Assets	74	163	148	273	360	419
Long-Term Investments	-	-	0.00	23	72	109
Intangible Assets	72	162	144	161	137	113
Noncurrent Deferred & Refundable Income Taxes	-	-	0.00	86	144	190
Other Noncurrent Operating Assets	1.69	0.90	4.27	3.55	6.57	6.16
Total Liabilities & Shareholders' Equity	107	427	433	674	811	999
Total Liabilities	118	330	247	271	344	340
Total Current Liabilities	20	135	54	79	164	175
Short-Term Debt	-	0.00	2.00	2.00	15	16
Accounts Payable	6.36	2.56	1.00	3.79	18	14
Accrued Expenses	5.50	123	40	60	99	121
Current Employee Benefit Liabilities	7.92	8.94	9.17	12	24	19
Other Current Liabilities	0.12	0.31	1.36	1.62	7.81	5.67
Total Noncurrent Liabilities	98	195	193	192	181	165
Long-Term Debt	98	194	190	190	179	163
Other Noncurrent Operating Liabilities	0.16	1.11	3.18	2.50	2.11	1.95
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-423	97	187	403	467	659
Total Preferred & Common Equity	-423	97	187	403	467	659
Total Common Equity	-423	97	187	403	467	659
Common Stock	0.00	585	640	675	610	657
Retained Earnings	-423	-488	-454	-272	-143	2.22
Accumulated Other Comprehensive Income / (Loss)	-	-	0.00	-0.15	0.00	0.07

This table presents Harmony Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	643	715	760	778	847	858	928
Total Current Assets	382	418	456	463	480	458	522
Cash & Equivalents	261	288	317	325	333	317	387
Short-Term Investments	46	56	54	46	39	30	23
Accounts Receivable	55	53	64	67	80	83	82
Inventories, net	3.90	4.09	4.85	5.09	5.86	5.64	6.92
Prepaid Expenses	11	11	9.44	14	13	16	16
Other Current Assets	4.11	6.15	6.55	5.70	8.68	6.51	7.46
Plant, Property, & Equipment, net	0.68	0.47	0.57	0.43	0.21	0.75	0.75
Total Noncurrent Assets	261	248	304	314	367	399	405
Long-Term Investments	8.28	-	59	68	81	87	94
Intangible Assets	167	155	149	143	131	125	119
Noncurrent Deferred & Refundable Income Taxes	82	89	94	100	148	180	185
Other Noncurrent Operating Assets	3.83	3.62	2.71	3.09	7.24	6.74	6.52
Total Liabilities & Shareholders' Equity	643	715	760	778	847	858	928
Total Liabilities	300	272	275	296	332	320	331
Total Current Liabilities	107	85	93	112	154	147	161
Short-Term Debt	2.00	6.50	11	15	15	15	15
Accounts Payable	10	6.41	6.56	6.54	15	23	11
Accrued Expenses	86	57	64	73	92	92	110
Current Employee Benefit Liabilities	8.33	5.69	7.97	10	7.32	9.64	14
Other Current Liabilities	1.37	9.95	3.95	7.79	25	7.61	12
Total Noncurrent Liabilities	192	187	182	184	177	173	170
Long-Term Debt	190	185	180	182	175	171	168
Other Noncurrent Operating Liabilities	2.50	1.63	1.48	1.90	2.34	1.80	2.21
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	344	443	485	481	515	539	597
Total Preferred & Common Equity	344	443	485	481	515	539	597
Total Common Equity	344	443	485	481	515	539	597
Common Stock	665	686	694	652	621	632	644
Retained Earnings	-321	-243	-208	-170	-105	-93	-47
Accumulated Other Comprehensive Income / (Loss)	-0.18	-0.03	-0.52	-0.52	-0.17	-0.23	0.50

This table displays calculated financial ratios and metrics derived from Harmony Biosciences' official financial filings.

Metric	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	2,564.59%	91.21%	43.35%	32.93%	22.80%
EBITDA Growth	0.00%	118.69%	308.91%	33.46%	48.96%	-1.22%
EBIT Growth	0.00%	109.54%	529.13%	37.48%	59.55%	-0.66%
NOPAT Growth	0.00%	111.64%	580.46%	157.50%	-31.50%	1.44%
Net Income Growth	0.00%	75.69%	193.65%	424.52%	-28.99%	12.91%
EPS Growth	0.00%	89.70%	123.39%	412.07%	-28.28%	17.84%
Operating Cash Flow Growth	0.00%	96.04%	3,401.74%	46.58%	51.86%	0.20%
Free Cash Flow Firm Growth	0.00%	0.00%	-104.32%	21,912.47%	50.96%	-25.07%
Invested Capital Growth	0.00%	1.45%	129.59%	72.56%	-5.58%	11.68%
Revenue Q/Q Growth	0.00%	0.00%	12.91%	9.26%	7.40%	4.82%
EBITDA Q/Q Growth	0.00%	0.00%	22.99%	15.91%	-3.52%	7.85%
EBIT Q/Q Growth	0.00%	0.00%	31.36%	18.77%	-3.74%	8.84%
NOPAT Q/Q Growth	0.00%	0.00%	30.26%	12.48%	-15.61%	18.07%
Net Income Q/Q Growth	0.00%	0.00%	196.28%	16.57%	-14.53%	18.65%
EPS Q/Q Growth	0.00%	0.00%	-89.45%	16.02%	-13.41%	18.40%
Operating Cash Flow Q/Q Growth	0.00%	91.94%	38.67%	-6.99%	29.51%	-0.50%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-13.60%	5.38%	33.73%
Invested Capital Q/Q Growth	0.00%	0.00%	-6.61%	13.32%	-2.15%	-4.58%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	73.69%	82.64%	81.82%	80.93%	79.17%	78.06%
EBITDA Margin	-2,370.34%	16.63%	35.56%	33.11%	37.10%	29.84%
Operating Margin	-2,433.76%	10.63%	28.66%	27.45%	32.99%	26.70%
EBIT Margin	-2,433.76%	8.71%	28.66%	27.49%	32.99%	26.69%
Profit (Net Income) Margin	-2,535.06%	-23.13%	11.33%	41.44%	22.14%	20.36%
Tax Burden Percent	100.00%	100.00%	92.44%	173.35%	74.31%	75.86%
Interest Burden Percent	104.16%	-265.50%	42.75%	86.98%	90.30%	100.55%
Effective Tax Rate	0.00%	0.00%	7.56%	-73.35%	25.69%	24.15%
Return on Invested Capital (ROIC)	-164.99%	19.07%	78.18%	106.03%	59.00%	58.22%
ROIC Less NNEP Spread (ROIC-NNEP)	-232.81%	-230.66%	198.93%	133.39%	66.17%	57.98%
Return on Net Nonoperating Assets (RNNOA)	1,476.60%	-105.39%	-53.79%	-44.45%	-29.37%	-32.38%
Return on Equity (ROE)	1,311.62%	-86.32%	24.39%	61.58%	29.63%	25.84%
Cash Return on Invested Capital (CROIC)	0.00%	17.63%	-0.46%	52.78%	64.74%	47.18%
Operating Return on Assets (OROA)	-136.74%	5.21%	20.35%	21.74%	25.86%	21.07%
Return on Assets (ROA)	-142.43%	-13.84%	8.04%	32.78%	17.35%	16.07%
Return on Common Equity (ROCE)	47,866.81%	328.47%	24.39%	61.58%	29.63%	25.84%
Return on Equity Simple (ROE_SIMPLE)	35.94%	-38.02%	18.55%	45.05%	27.59%	22.07%
Net Operating Profit after Tax (NOPAT)	-102	12	81	208	143	145
NOPAT Margin	-1,703.63%	7.44%	26.49%	47.58%	24.52%	20.25%
Net Nonoperating Expense Percent (NNEP)	67.82%	249.73%	-120.75%	-27.37%	-7.17%	0.24%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	35.04%	21.60%	17.26%
Cost of Revenue to Revenue	26.31%	17.36%	18.18%	19.07%	20.83%	21.94%
SG&A Expenses to Revenue	607.32%	24.88%	20.92%	19.19%	16.37%	15.44%
R&D to Revenue	1,160.88%	12.17%	9.94%	16.19%	13.07%	20.40%
Operating Expenses to Revenue	2,507.46%	72.00%	53.17%	53.49%	46.18%	51.36%
Earnings before Interest and Taxes (EBIT)	-146	14	88	120	192	191
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-142	27	109	145	216	213
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	21.16	13.37	8.11	4.05	2.98
Price to Tangible Book Value (P/TBV)	0.00	0.00	58.54	13.51	5.74	3.59
Price to Revenue (P/Rev)	21.41	12.87	8.16	7.46	3.25	2.75
Price to Earnings (P/E)	0.00	0.00	72.06	18.03	14.67	13.48
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	1.39%	5.55%	6.82%	7.42%
Enterprise Value to Invested Capital (EV/IC)	9.90	32.20	17.00	12.52	7.07	5.97
Enterprise Value to Revenue (EV/Rev)	102.27	12.66	8.02	7.11	2.85	2.19
Enterprise Value to EBITDA (EV/EBITDA)	0.00	76.12	22.56	21.48	7.69	7.34
Enterprise Value to EBIT (EV/EBIT)	0.00	145.32	28.00	25.88	8.64	8.21
Enterprise Value to NOPAT (EV/NOPAT)	0.00	170.07	30.29	14.95	11.63	10.82
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	24.87	21.56	7.57	7.12
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	183.91	0.00	30.03	10.60	13.35
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	-8.45	2.00	1.03	0.48	0.41	0.27
Long-Term Debt to Equity	-8.45	2.00	1.02	0.47	0.38	0.25
Financial Leverage	-6.34	0.46	-0.27	-0.33	-0.44	-0.56
Leverage Ratio	-9.21	6.24	3.03	1.88	1.71	1.61
Compound Leverage Factor	-9.59	-16.56	1.30	1.63	1.54	1.62
Debt to Total Capital	113.42%	66.65%	50.72%	32.24%	29.30%	21.38%
Short-Term Debt to Total Capital	0.00%	0.00%	0.53%	0.34%	2.27%	1.94%
Long-Term Debt to Total Capital	113.42%	66.65%	50.20%	31.90%	27.03%	19.44%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	476.24%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-489.66%	33.35%	49.28%	67.76%	70.70%	78.62%
Debt to EBITDA	-0.69	7.31	1.77	1.32	0.90	0.84
Net Debt to EBITDA	-0.52	-1.29	-0.39	-1.06	-1.07	-1.86
Long-Term Debt to EBITDA	-0.69	7.31	1.75	1.31	0.83	0.76
Debt to NOPAT	-0.96	16.34	2.37	0.92	1.36	1.24
Net Debt to NOPAT	-0.72	-2.89	-0.52	-0.74	-1.63	-2.74
Long-Term Debt to NOPAT	-0.96	16.34	2.35	0.91	1.25	1.13
Altman Z-Score	-9.22	2.98	6.60	8.48	4.97	5.30
Noncontrolling Interest Sharing Ratio	-3,549.45%	480.50%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	1.58	1.95	5.29	5.07	2.75	3.31
Quick Ratio	1.44	1.86	5.01	4.79	2.61	3.14
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	11	-0.48	104	157	117
Operating Cash Flow to CapEx	-50,628.19%	-149,250.00%	33,072.82%	83,991.86%	588.50%	642.34%
Free Cash Flow to Firm to Interest Expense	0.00	0.49	-0.01	5.52	4.67	6.71
Operating Cash Flow to Interest Expense	0.00	-0.13	1.96	7.69	6.54	12.56
Operating Cash Flow Less CapEx to Interest Expense	0.00	-0.13	1.95	7.68	5.43	10.61
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.06	0.60	0.71	0.79	0.78	0.79
Accounts Receivable Turnover	1.41	12.09	10.71	9.78	9.03	9.09
Inventory Turnover	1.45	11.30	13.45	19.13	25.10	24.97
Fixed Asset Turnover	4.51	140.87	347.49	628.65	1,233.10	878.05
Accounts Payable Turnover	0.25	6.22	31.22	34.88	11.27	9.96
Days Sales Outstanding (DSO)	259.06	30.20	34.07	37.34	40.41	40.13
Days Inventory Outstanding (DIO)	251.82	32.31	27.14	19.08	14.54	14.62
Days Payable Outstanding (DPO)	1,472.04	58.66	11.69	10.47	32.39	36.63
Cash Conversion Cycle (CCC)	-961.15	3.85	49.51	45.96	22.56	18.12
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	62	63	144	249	235	262
Invested Capital Turnover	0.10	2.56	2.95	2.23	2.41	2.87
Increase / (Decrease) in Invested Capital	0.00	0.90	81	105	-14	27
Enterprise Value (EV)	613	2,022	2,451	3,114	1,660	1,566
Market Capitalization	128	2,057	2,493	3,268	1,892	1,962
Book Value per Share	($54.37)	$1.71	$3.19	$6.79	$7.97	$11.56
Tangible Book Value per Share	($63.65)	($1.15)	$0.73	$4.08	$5.63	$9.57
Total Capital	86	291	378	594	661	838
Total Debt	98	194	192	192	194	179
Total Long-Term Debt	98	194	190	190	179	163
Net Debt	73	-34	-42	-154	-232	-397
Capital Expenditures (CapEx)	0.15	0.00	0.30	0.17	37	34
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-13	-100	-1.65	0.29	-51	-47
Debt-free Net Working Capital (DFNWC)	12	128	233	323	302	420
Net Working Capital (NWC)	12	128	231	321	287	404
Net Nonoperating Expense (NNE)	50	49	46	27	14	-0.74
Net Nonoperating Obligations (NNO)	73	-34	-42	-154	-232	-397
Total Depreciation and Amortization (D&A)	3.80	13	21	25	24	23
Debt-free, Cash-free Net Working Capital to Revenue	-214.38%	-62.78%	-0.54%	0.07%	-8.79%	-6.54%
Debt-free Net Working Capital to Revenue	193.58%	80.35%	76.17%	73.86%	51.94%	58.82%
Net Working Capital to Revenue	193.58%	80.35%	75.52%	73.40%	49.36%	56.55%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($2.48)	$0.60	$3.07	$2.17	$2.56
Adjusted Weighted Average Basic Shares Outstanding	0.00	25.77M	57.53M	59.17M	59.47M	56.89M
Adjusted Diluted Earnings per Share	$0.00	($2.48)	$0.58	$2.97	$2.13	$2.51
Adjusted Weighted Average Diluted Shares Outstanding	0.00	25.77M	59.21M	61.10M	60.37M	57.87M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	56.89M	58.87M	59.62M	56.77M	57.35M
Normalized Net Operating Profit after Tax (NOPAT)	-102	12	81	84	143	145
Normalized NOPAT Margin	-1,703.63%	7.44%	26.49%	19.21%	24.52%	20.25%
Pre Tax Income Margin	-2,535.06%	-23.13%	12.25%	23.91%	29.79%	26.84%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.61	1.74	6.40	5.73	10.90
NOPAT to Interest Expense	0.00	0.53	1.61	11.08	4.26	8.27
EBIT Less CapEx to Interest Expense	0.00	0.61	1.73	6.39	4.62	8.95
NOPAT Less CapEx to Interest Expense	0.00	0.53	1.60	11.08	3.14	6.32
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.45%	0.87%	0.00%	77.61%	0.00%

This table displays calculated financial ratios and metrics derived from Harmony Biosciences' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	45.18%	40.67%	39.63%	25.40%	36.74%	31.26%	29.79%	28.76%	16.08%	19.51%
EBITDA Growth	-29.58%	58.82%	39.51%	32.96%	285.83%	-14.74%	24.49%	-48.76%	-5.57%	34.29%
EBIT Growth	-43.21%	66.37%	46.71%	41.36%	439.47%	-15.71%	28.37%	-54.36%	-4.52%	39.04%
NOPAT Growth	791.41%	97.10%	24.61%	36.86%	-63.56%	-48.54%	22.09%	-68.72%	-4.42%	82.20%
Net Income Growth	1,014.17%	113.56%	37.24%	45.77%	-56.27%	-45.15%	30.01%	-66.21%	19.84%	85.95%
EPS Growth	947.06%	107.89%	37.14%	43.59%	-56.25%	-41.77%	39.58%	-64.29%	25.40%	84.78%
Operating Cash Flow Growth	81.45%	-28.92%	47.51%	9.88%	14.30%	187.37%	-26.83%	14.99%	11.73%	-1.44%
Free Cash Flow Firm Growth	189.46%	4.68%	-670.23%	-420.44%	-58.68%	178.12%	200.59%	-4.38%	-60.18%	-46.92%
Invested Capital Growth	42.22%	72.56%	33.14%	37.68%	9.35%	-5.58%	3.97%	17.77%	14.52%	11.68%
Revenue Q/Q Growth	9.51%	9.47%	-7.16%	12.67%	19.41%	5.08%	-8.19%	11.77%	7.65%	8.19%
EBITDA Q/Q Growth	-53.47%	191.49%	-13.91%	13.86%	35.03%	-35.59%	25.18%	-53.14%	148.86%	-8.40%
EBIT Q/Q Growth	-63.94%	298.81%	-15.23%	15.95%	37.62%	-37.68%	28.48%	-58.77%	187.88%	-9.25%
NOPAT Q/Q Growth	392.78%	-60.14%	-39.76%	15.65%	31.20%	-43.71%	42.94%	-70.38%	300.97%	7.31%
Net Income Q/Q Growth	273.73%	-44.84%	-39.22%	16.33%	12.13%	-30.82%	44.07%	-69.76%	297.66%	7.34%
EPS Q/Q Growth	269.23%	-45.14%	-39.24%	16.67%	12.50%	-26.98%	45.65%	-70.15%	295.00%	7.59%
Operating Cash Flow Q/Q Growth	63.66%	-51.67%	59.53%	-12.91%	70.25%	21.50%	-59.38%	36.85%	65.43%	7.18%
Free Cash Flow Firm Q/Q Growth	581.52%	-178.95%	45.00%	-8.28%	187.87%	49.28%	-29.18%	-212.36%	133.52%	98.99%
Invested Capital Q/Q Growth	22.37%	13.32%	-2.66%	2.00%	-2.81%	-2.15%	7.18%	15.54%	-5.49%	-4.58%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	80.41%	79.05%	82.56%	81.37%	79.85%	74.38%	82.22%	81.40%	77.01%	72.97%
EBITDA Margin	15.73%	41.89%	38.84%	39.25%	44.39%	27.21%	37.26%	15.62%	36.11%	30.57%
Operating Margin	10.15%	37.11%	33.93%	34.95%	40.25%	23.87%	33.65%	12.36%	33.17%	27.69%
EBIT Margin	10.20%	37.17%	33.93%	34.92%	40.25%	23.87%	33.56%	12.38%	33.10%	27.77%
Profit (Net Income) Margin	75.03%	37.81%	24.75%	25.56%	24.00%	15.80%	24.79%	6.71%	24.78%	24.58%
Tax Burden Percent	1,103.84%	109.99%	78.04%	77.79%	74.20%	67.04%	74.03%	53.43%	74.14%	88.10%
Interest Burden Percent	66.63%	92.49%	93.46%	94.08%	80.35%	98.74%	99.79%	101.41%	100.95%	100.48%
Effective Tax Rate	-1,003.84%	-9.99%	21.96%	22.21%	25.80%	32.96%	25.97%	46.57%	25.86%	11.90%
Return on Invested Capital (ROIC)	240.24%	90.95%	58.91%	63.60%	70.43%	38.50%	62.28%	16.11%	65.12%	70.12%
ROIC Less NNEP Spread (ROIC-NNEP)	311.45%	94.88%	60.67%	65.03%	75.57%	38.68%	62.36%	16.03%	65.00%	70.00%
Return on Net Nonoperating Assets (RNNOA)	-76.59%	-31.61%	-21.54%	-27.13%	-33.48%	-17.17%	-30.22%	-7.61%	-33.95%	-39.09%
Return on Equity (ROE)	163.64%	59.34%	37.37%	36.47%	36.95%	21.33%	32.06%	8.50%	31.17%	31.03%
Cash Return on Invested Capital (CROIC)	64.20%	52.78%	71.41%	71.24%	64.65%	64.74%	56.69%	29.83%	34.07%	47.18%
Operating Return on Assets (OROA)	7.90%	29.39%	27.15%	27.54%	30.69%	18.71%	26.54%	10.04%	26.46%	21.92%
Return on Assets (ROA)	58.13%	29.90%	19.80%	20.15%	18.30%	12.38%	19.60%	5.44%	19.81%	19.41%
Return on Common Equity (ROCE)	163.64%	59.34%	37.37%	36.47%	36.95%	21.33%	32.06%	8.50%	31.17%	31.03%
Return on Equity Simple (ROE_SIMPLE)	45.27%	0.00%	42.77%	41.27%	31.32%	0.00%	26.72%	21.35%	20.55%	0.00%
Net Operating Profit after Tax (NOPAT)	131	52	32	36	48	27	39	11	46	49
NOPAT Margin	112.08%	40.82%	26.48%	27.18%	29.87%	16.00%	24.91%	6.60%	24.59%	24.39%
Net Nonoperating Expense Percent (NNEP)	-71.22%	-3.93%	-1.77%	-1.43%	-5.15%	-0.18%	-0.08%	0.07%	0.12%	0.12%
Return On Investment Capital (ROIC_SIMPLE)	-	8.81%	-	-	-	4.08%	-	-	-	5.86%
Cost of Revenue to Revenue	19.59%	20.95%	17.44%	18.63%	20.15%	25.62%	17.78%	18.60%	22.99%	27.03%
SG&A Expenses to Revenue	18.20%	17.65%	18.52%	16.99%	14.07%	16.55%	16.61%	15.75%	15.37%	14.34%
R&D to Revenue	34.60%	7.87%	11.16%	11.15%	10.92%	18.00%	14.35%	36.79%	13.65%	17.22%
Operating Expenses to Revenue	70.26%	41.94%	48.62%	46.42%	39.60%	50.51%	48.57%	69.04%	43.84%	45.28%
Earnings before Interest and Taxes (EBIT)	12	48	40	47	65	40	52	21	62	56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	18	54	46	53	71	46	58	27	67	62
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.62	8.11	4.39	4.35	4.08	4.05	0.00	3.18	3.81	2.98
Price to Tangible Book Value (P/TBV)	14.81	13.51	6.76	6.28	5.81	5.74	0.00	4.14	4.76	3.59
Price to Revenue (P/Rev)	6.54	7.46	4.13	4.23	3.63	3.25	0.00	2.61	3.33	2.75
Price to Earnings (P/E)	16.09	18.03	10.28	10.56	13.07	14.67	0.00	14.86	18.39	13.48
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	6.22%	5.55%	9.73%	9.47%	7.65%	6.82%	0.00%	6.73%	5.44%	7.42%
Enterprise Value to Invested Capital (EV/IC)	11.37	12.52	7.41	7.58	7.18	7.07	0.00	5.04	7.10	5.97
Enterprise Value to Revenue (EV/Rev)	6.23	7.11	3.80	3.75	3.18	2.85	0.00	2.23	2.86	2.19
Enterprise Value to EBITDA (EV/EBITDA)	19.96	21.48	11.35	10.94	7.71	7.69	0.00	7.27	9.87	7.34
Enterprise Value to EBIT (EV/EBIT)	24.63	25.88	13.47	12.74	8.65	8.64	0.00	8.23	11.14	8.21
Enterprise Value to NOPAT (EV/NOPAT)	13.48	14.95	8.48	8.53	10.20	11.63	0.00	11.81	15.92	10.82
Enterprise Value to Operating Cash Flow (EV/OCF)	16.07	21.56	11.34	11.59	10.18	7.57	0.00	6.86	8.83	7.12
Enterprise Value to Free Cash Flow (EV/FCFF)	20.79	30.03	11.85	12.32	11.61	10.60	0.00	18.27	22.24	13.35
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.56	0.48	0.43	0.39	0.41	0.41	0.37	0.35	0.31	0.27
Long-Term Debt to Equity	0.55	0.47	0.42	0.37	0.38	0.38	0.34	0.32	0.28	0.25
Financial Leverage	-0.25	-0.33	-0.36	-0.42	-0.44	-0.44	-0.48	-0.47	-0.52	-0.56
Leverage Ratio	2.09	1.88	1.79	1.73	1.72	1.71	1.63	1.58	1.58	1.61
Compound Leverage Factor	1.39	1.74	1.68	1.63	1.38	1.69	1.63	1.60	1.60	1.62
Debt to Total Capital	35.80%	32.24%	30.19%	28.30%	29.06%	29.30%	26.93%	25.71%	23.45%	21.38%
Short-Term Debt to Total Capital	0.37%	0.34%	1.02%	1.63%	2.21%	2.27%	2.13%	2.07%	1.92%	1.94%
Long-Term Debt to Total Capital	35.42%	31.90%	29.16%	26.67%	26.84%	27.03%	24.81%	23.64%	21.53%	19.44%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	64.20%	67.76%	69.81%	71.70%	70.94%	70.70%	73.07%	74.29%	76.55%	78.62%
Debt to EBITDA	1.53	1.32	1.21	1.12	0.88	0.90	0.84	0.92	0.92	0.84
Net Debt to EBITDA	-0.99	-1.06	-0.96	-1.39	-1.08	-1.07	-1.16	-1.23	-1.63	-1.86
Long-Term Debt to EBITDA	1.52	1.31	1.17	1.05	0.81	0.83	0.77	0.85	0.85	0.76
Debt to NOPAT	1.04	0.92	0.90	0.87	1.17	1.36	1.27	1.50	1.49	1.24
Net Debt to NOPAT	-0.67	-0.74	-0.72	-1.08	-1.43	-1.63	-1.76	-2.00	-2.63	-2.74
Long-Term Debt to NOPAT	1.02	0.91	0.87	0.82	1.08	1.25	1.17	1.38	1.37	1.13
Altman Z-Score	5.75	8.13	5.22	5.65	5.19	4.35	0.00	4.34	5.47	4.85
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.56	5.07	4.90	4.90	4.12	2.75	3.11	3.13	3.24	3.31
Quick Ratio	3.38	4.79	4.64	4.67	3.90	2.61	2.93	2.93	3.05	3.14
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	66	-52	-29	-31	27	41	29	-32	11	22
Operating Cash Flow to CapEx	64,191.86%	0.00%	0.00%	18,079.51%	0.00%	206.79%	622,820.00%	6,743.20%	2,350,033.33%	225.01%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-5.01	-5.00	1.63	8.51	6.37	-7.38	2.50	5.15
Operating Cash Flow to Interest Expense	0.00	0.00	7.43	5.96	3.76	15.99	6.87	9.68	16.21	17.95
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	7.43	5.93	3.76	8.26	6.87	9.53	16.21	9.97
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.77	0.79	0.80	0.79	0.76	0.78	0.79	0.81	0.80	0.79
Accounts Receivable Turnover	9.08	9.78	10.40	8.78	8.86	9.03	9.34	8.93	9.17	9.09
Inventory Turnover	17.10	19.13	20.62	21.11	23.36	25.10	25.72	25.74	24.26	24.97
Fixed Asset Turnover	495.68	628.65	774.50	787.46	978.19	1,233.10	1,808.23	989.61	1,157.69	878.05
Accounts Payable Turnover	10.46	34.88	13.45	14.46	12.66	11.27	11.87	9.24	17.05	9.96
Days Sales Outstanding (DSO)	40.20	37.34	35.10	41.57	41.20	40.41	39.10	40.88	39.82	40.13
Days Inventory Outstanding (DIO)	21.35	19.08	17.70	17.29	15.62	14.54	14.19	14.18	15.05	14.62
Days Payable Outstanding (DPO)	34.89	10.47	27.14	25.24	28.84	32.39	30.75	39.51	21.40	36.63
Cash Conversion Cycle (CCC)	26.65	45.96	25.66	33.63	27.98	22.56	22.54	15.55	33.46	18.12
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	220	249	242	247	240	235	252	291	275	262
Invested Capital Turnover	2.14	2.23	2.22	2.34	2.36	2.41	2.50	2.44	2.65	2.87
Increase / (Decrease) in Invested Capital	65	105	60	68	21	-14	9.61	44	35	27
Enterprise Value (EV)	2,496	3,114	1,794	1,872	1,725	1,660	0.00	1,466	1,952	1,566
Market Capitalization	2,620	3,268	1,947	2,110	1,966	1,892	0.00	1,713	2,273	1,962
Book Value per Share	$5.81	$6.79	$7.43	$8.09	$8.02	$7.97	$9.08	$9.48	$10.50	$11.56
Tangible Book Value per Share	$2.99	$4.08	$4.83	$5.61	$5.64	$5.63	$6.77	$7.28	$8.40	$9.57
Total Capital	536	594	635	677	678	661	705	725	780	838
Total Debt	192	192	192	191	197	194	190	186	183	179
Total Long-Term Debt	190	190	185	180	182	179	175	171	168	163
Net Debt	-124	-154	-152	-238	-241	-232	-264	-248	-322	-397
Capital Expenditures (CapEx)	0.09	0.00	0.00	0.21	0.00	37	0.01	0.63	0.00	34
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-31	0.29	-4.65	2.61	-5.08	-51	-32	-20	-34	-47
Debt-free Net Working Capital (DFNWC)	277	323	339	374	366	302	340	327	376	420
Net Working Capital (NWC)	275	321	333	363	351	287	325	312	361	404
Net Nonoperating Expense (NNE)	43	3.86	2.06	2.18	9.41	0.34	0.18	-0.18	-0.34	-0.38
Net Nonoperating Obligations (NNO)	-124	-154	-201	-238	-241	-232	-264	-248	-322	-397
Total Depreciation and Amortization (D&A)	6.48	6.06	5.84	5.81	6.64	5.63	5.71	5.60	5.59	5.65
Debt-free, Cash-free Net Working Capital to Revenue	-7.74%	0.07%	-0.99%	0.52%	-0.94%	-8.79%	-5.20%	-3.07%	-5.04%	-6.54%
Debt-free Net Working Capital to Revenue	69.05%	73.86%	71.92%	74.89%	67.46%	51.94%	55.10%	49.80%	55.16%	58.82%
Net Working Capital to Revenue	68.55%	73.40%	70.54%	72.69%	64.69%	49.36%	52.67%	47.52%	52.96%	56.55%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.48	$0.83	$0.49	$0.57	$0.64	$0.47	$0.68	$0.20	$0.81	$0.87
Adjusted Weighted Average Basic Shares Outstanding	59.23M	59.17M	59.73M	59.97M	59.86M	59.47M	56.77M	56.80M	56.87M	56.89M
Adjusted Diluted Earnings per Share	$1.44	$0.79	$0.48	$0.56	$0.63	$0.46	$0.67	$0.20	$0.79	$0.85
Adjusted Weighted Average Diluted Shares Outstanding	61.21M	61.10M	61.22M	60.74M	60.68M	60.37M	57.60M	57.54M	58.10M	57.87M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	59.32M	59.62M	59.95M	60.00M	58.57M	56.77M	56.79M	56.83M	57.03M	57.35M
Normalized Net Operating Profit after Tax (NOPAT)	8.33	33	32	36	48	27	39	11	46	49
Normalized NOPAT Margin	7.11%	25.98%	26.48%	27.18%	29.87%	16.00%	24.91%	6.60%	24.59%	24.39%
Pre Tax Income Margin	6.80%	34.37%	31.71%	32.85%	32.34%	23.57%	33.49%	12.55%	33.42%	27.90%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	7.05	7.54	3.84	8.38	11.44	4.86	14.16	13.28
NOPAT to Interest Expense	0.00	0.00	5.50	5.87	2.85	5.62	8.49	2.59	10.52	11.67
EBIT Less CapEx to Interest Expense	0.00	0.00	7.05	7.51	3.84	0.65	11.44	4.71	14.16	5.30
NOPAT Less CapEx to Interest Expense	0.00	0.00	5.50	5.83	2.85	-2.11	8.49	2.45	10.52	3.69
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	33.17%	77.61%	0.00%	0.00%	40.77%	0.00%

Frequently Asked Questions About Harmony Biosciences' Financials

When does Harmony Biosciences's financial year end?

According to the most recent income statement we have on file, Harmony Biosciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Harmony Biosciences' net income changed over the last 5 years?

Harmony Biosciences' net income appears to be on an upward trend, with a most recent value of $145.49 million in 2024, falling from -$151.98 million in 2019. The previous period was $128.85 million in 2023.

What is Harmony Biosciences's operating income?

Harmony Biosciences's total operating income in 2024 was $190.83 million, based on the following breakdown:

Total Gross Profit: $557.92 million
Total Operating Expenses: $367.09 million

How has Harmony Biosciences revenue changed over the last 5 years?

Over the last 5 years, Harmony Biosciences' total revenue changed from $6.00 million in 2019 to $714.73 million in 2024, a change of 11,822.2%.

How much debt does Harmony Biosciences have?

Harmony Biosciences' total liabilities were at $340.05 million at the end of 2024, a 1.3% decrease from 2023, and a 187.5% increase since 2019.

How much cash does Harmony Biosciences have?

In the past 5 years, Harmony Biosciences' cash and equivalents has ranged from $24.46 million in 2019 to $453.00 million in 2024, and is currently $453.00 million as of their latest financial filing in 2024.

How has Harmony Biosciences' book value per share changed over the last 5 years?

Over the last 5 years, Harmony Biosciences' book value per share changed from -54.37 in 2019 to 11.56 in 2024, a change of -121.3%.

Related Companies

This page (NASDAQ:HRMY) was last updated on 4/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harmony Biosciences (HRMY) Financials

Frequently Asked Questions About Harmony Biosciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harmony Biosciences (HRMY) Financials

Annual Income Statements for Harmony Biosciences

Quarterly Income Statements for Harmony Biosciences

Annual Cash Flow Statements for Harmony Biosciences

Quarterly Cash Flow Statements for Harmony Biosciences

Annual Balance Sheets for Harmony Biosciences

Quarterly Balance Sheets for Harmony Biosciences

Annual Metrics and Ratios for Harmony Biosciences

Quarterly Metrics and Ratios for Harmony Biosciences

Frequently Asked Questions About Harmony Biosciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools